Kymera Therapeutics KYMR Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kymera Therapeutics's accrued liabilities, current?
- Kymera Therapeutics (KYMR) reported accrued liabilities, current of $35.1M in Q1 2026.
- How has Kymera Therapeutics's accrued liabilities, current changed year-over-year?
- Kymera Therapeutics's accrued liabilities, current increased by 51.8% year-over-year, from $23.12M to $35.1M.
- What is the long-term trend for Kymera Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), Kymera Therapeutics's accrued liabilities, current has grown at a 32.6% compound annual growth rate (CAGR), from $10.33M to $42.27M.